Impact of a venous thromboembolism prophylaxis "smart order set": Improved compliance, fewer events

Amer M. Zeidan, Michael B Streiff, Brandyn Lau, Syed Rafay Ahmed, Peggy S. Kraus, Deborah B. Hobson, Howard Carolan, Chryso Lambrianidi, Paula B. Horn, Kenneth M Shermock, Gabriel Tinoco, Salahuddin Siddiqui, Elliott Haut

Research output: Contribution to journalArticle

Abstract

Venous thromboembolism (VTE) affects over 700,000 Americans annually. Prophylaxis reduces the risk of VTE by 60% but many patients still do not receive risk-appropriate VTE prophylaxis. To improve our institution's VTE prophylaxis performance, we developed mandatory computerized clinical decision support-enabled "smart order sets" that required providers to assess VTE risk factors and contraindications to pharmacologic prophylaxis. Using provider responses, the order set recommends evidence-based risk-appropriate VTE prophylaxis. To study the impact of our "smart order set" on prescription of risk-appropriate VTE prophylaxis and clinical outcomes, we conducted a retrospective chart review of consecutive patients admitted to the Medicine service during one month immediately prior to (November 2007) and a single month subsequent to (April 2010) order set launch. Data collection included patient demographics, VTE risk factors, and the use and type of VTE prophylaxis. The pre- and post-implementation cohorts contained 1,000 and 942 patients, respectively. After implementation of the "smart order set", the prescription of risk-appropriate VTE prophylaxis increased from 65.6% to 90.1% (P

Original languageEnglish (US)
Pages (from-to)545-549
Number of pages5
JournalAmerican Journal of Hematology
Volume88
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Venous Thromboembolism
Compliance
Prescriptions
Clinical Decision Support Systems
Medicine
Demography

ASJC Scopus subject areas

  • Hematology

Cite this

Impact of a venous thromboembolism prophylaxis "smart order set" : Improved compliance, fewer events. / Zeidan, Amer M.; Streiff, Michael B; Lau, Brandyn; Ahmed, Syed Rafay; Kraus, Peggy S.; Hobson, Deborah B.; Carolan, Howard; Lambrianidi, Chryso; Horn, Paula B.; Shermock, Kenneth M; Tinoco, Gabriel; Siddiqui, Salahuddin; Haut, Elliott.

In: American Journal of Hematology, Vol. 88, No. 7, 07.2013, p. 545-549.

Research output: Contribution to journalArticle

Zeidan, AM, Streiff, MB, Lau, B, Ahmed, SR, Kraus, PS, Hobson, DB, Carolan, H, Lambrianidi, C, Horn, PB, Shermock, KM, Tinoco, G, Siddiqui, S & Haut, E 2013, 'Impact of a venous thromboembolism prophylaxis "smart order set": Improved compliance, fewer events', American Journal of Hematology, vol. 88, no. 7, pp. 545-549. https://doi.org/10.1002/ajh.23450
Zeidan, Amer M. ; Streiff, Michael B ; Lau, Brandyn ; Ahmed, Syed Rafay ; Kraus, Peggy S. ; Hobson, Deborah B. ; Carolan, Howard ; Lambrianidi, Chryso ; Horn, Paula B. ; Shermock, Kenneth M ; Tinoco, Gabriel ; Siddiqui, Salahuddin ; Haut, Elliott. / Impact of a venous thromboembolism prophylaxis "smart order set" : Improved compliance, fewer events. In: American Journal of Hematology. 2013 ; Vol. 88, No. 7. pp. 545-549.
@article{93903767a34d4a8d999a7bb665b5e86f,
title = "Impact of a venous thromboembolism prophylaxis {"}smart order set{"}: Improved compliance, fewer events",
abstract = "Venous thromboembolism (VTE) affects over 700,000 Americans annually. Prophylaxis reduces the risk of VTE by 60{\%} but many patients still do not receive risk-appropriate VTE prophylaxis. To improve our institution's VTE prophylaxis performance, we developed mandatory computerized clinical decision support-enabled {"}smart order sets{"} that required providers to assess VTE risk factors and contraindications to pharmacologic prophylaxis. Using provider responses, the order set recommends evidence-based risk-appropriate VTE prophylaxis. To study the impact of our {"}smart order set{"} on prescription of risk-appropriate VTE prophylaxis and clinical outcomes, we conducted a retrospective chart review of consecutive patients admitted to the Medicine service during one month immediately prior to (November 2007) and a single month subsequent to (April 2010) order set launch. Data collection included patient demographics, VTE risk factors, and the use and type of VTE prophylaxis. The pre- and post-implementation cohorts contained 1,000 and 942 patients, respectively. After implementation of the {"}smart order set{"}, the prescription of risk-appropriate VTE prophylaxis increased from 65.6{\%} to 90.1{\%} (P",
author = "Zeidan, {Amer M.} and Streiff, {Michael B} and Brandyn Lau and Ahmed, {Syed Rafay} and Kraus, {Peggy S.} and Hobson, {Deborah B.} and Howard Carolan and Chryso Lambrianidi and Horn, {Paula B.} and Shermock, {Kenneth M} and Gabriel Tinoco and Salahuddin Siddiqui and Elliott Haut",
year = "2013",
month = "7",
doi = "10.1002/ajh.23450",
language = "English (US)",
volume = "88",
pages = "545--549",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Impact of a venous thromboembolism prophylaxis "smart order set"

T2 - Improved compliance, fewer events

AU - Zeidan, Amer M.

AU - Streiff, Michael B

AU - Lau, Brandyn

AU - Ahmed, Syed Rafay

AU - Kraus, Peggy S.

AU - Hobson, Deborah B.

AU - Carolan, Howard

AU - Lambrianidi, Chryso

AU - Horn, Paula B.

AU - Shermock, Kenneth M

AU - Tinoco, Gabriel

AU - Siddiqui, Salahuddin

AU - Haut, Elliott

PY - 2013/7

Y1 - 2013/7

N2 - Venous thromboembolism (VTE) affects over 700,000 Americans annually. Prophylaxis reduces the risk of VTE by 60% but many patients still do not receive risk-appropriate VTE prophylaxis. To improve our institution's VTE prophylaxis performance, we developed mandatory computerized clinical decision support-enabled "smart order sets" that required providers to assess VTE risk factors and contraindications to pharmacologic prophylaxis. Using provider responses, the order set recommends evidence-based risk-appropriate VTE prophylaxis. To study the impact of our "smart order set" on prescription of risk-appropriate VTE prophylaxis and clinical outcomes, we conducted a retrospective chart review of consecutive patients admitted to the Medicine service during one month immediately prior to (November 2007) and a single month subsequent to (April 2010) order set launch. Data collection included patient demographics, VTE risk factors, and the use and type of VTE prophylaxis. The pre- and post-implementation cohorts contained 1,000 and 942 patients, respectively. After implementation of the "smart order set", the prescription of risk-appropriate VTE prophylaxis increased from 65.6% to 90.1% (P

AB - Venous thromboembolism (VTE) affects over 700,000 Americans annually. Prophylaxis reduces the risk of VTE by 60% but many patients still do not receive risk-appropriate VTE prophylaxis. To improve our institution's VTE prophylaxis performance, we developed mandatory computerized clinical decision support-enabled "smart order sets" that required providers to assess VTE risk factors and contraindications to pharmacologic prophylaxis. Using provider responses, the order set recommends evidence-based risk-appropriate VTE prophylaxis. To study the impact of our "smart order set" on prescription of risk-appropriate VTE prophylaxis and clinical outcomes, we conducted a retrospective chart review of consecutive patients admitted to the Medicine service during one month immediately prior to (November 2007) and a single month subsequent to (April 2010) order set launch. Data collection included patient demographics, VTE risk factors, and the use and type of VTE prophylaxis. The pre- and post-implementation cohorts contained 1,000 and 942 patients, respectively. After implementation of the "smart order set", the prescription of risk-appropriate VTE prophylaxis increased from 65.6% to 90.1% (P

UR - http://www.scopus.com/inward/record.url?scp=84879414621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879414621&partnerID=8YFLogxK

U2 - 10.1002/ajh.23450

DO - 10.1002/ajh.23450

M3 - Article

C2 - 23553743

AN - SCOPUS:84879414621

VL - 88

SP - 545

EP - 549

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -